ACTRN12617000557336
Terminated
Phase 1
A Phase 1a/1b, Blinded, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-1740 in Non Cirrhotic, HBV-DNA Negative and Positive Subjects with Chronic HBV Infection.
ConditionsChronic hepatitis B virus infection
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Chronic hepatitis B virus infection
- Sponsor
- Arbutus Biopharma Corporation
- Enrollment
- 30
- Status
- Terminated
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 1
A study to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of BJT-678 in Healthy volunteersChronic Hepatitis D InfectionChronic Hepatitis B InfectionInfection - Other infectious diseasesACTRN12624001003561Bluejay Therapeutics, Inc.80
Active, not recruiting
Phase 1
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b when added to standard of care anticoagulation therapy in Subjects With Acute Submassive Pulmonary EmbolismDS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)MedDRA version: 20.0 Level: HLT Classification code 10037379 Term: Pulmonary embolism and thrombosis System Organ Class: 100000004866MedDRA version: 20.0 Level: PT Classification code 10037377 Term: Pulmonary embolism System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-005211-32-NLDaiichi Sankyo, Inc.116
Completed
Not Applicable
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to Standard of Care Anticoagulation Therapy in Subjects with Acute<br>Submassive Pulmonary Embolism.Pulmonary embolism10014523NL-OMON47535Daiichi Sankyo, Inc22
Not yet recruiting
Phase 1
A Study in Healthy Males and Females to Test How Different Doses of OPC-224333 are Tolerated (Arm 1)EpilepsyNeurological - EpilepsyACTRN12622000460707Otsuka Pharmaceutical Development & Commercialization, Inc72
Completed
Phase 1
A Trial in Healthy Participants to Evaluate the Pharmacokinetics, Safety, Tolerability and Food Effects of PRAX-562ACTRN12620001292965Praxis Precision Medicines112